Literature DB >> 2156043

Constitutive expression of HIV-1 tat protein in human Jurkat T cells using a BK virus vector.

A Caputo1, J G Sodroski, W A Haseltine.   

Abstract

The production and characterization of Jurkat cell lines that constitutively express functional human immune deficiency virus type 1 (HIV-1) tat protein, using a BK virus plasmid expression vector and HIV-1 tat cDNA, is described. An increased growth rate of these Jurkat-tat cell lines as compared with control cell lines was observed.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2156043

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN： 0894-9255


  23 in total

1.  The viral protein Tat can inhibit the establishment of HIV-1 latency.

Authors:  Daniel A Donahue; Björn D Kuhl; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

2.  Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1.

Authors:  Marta J Gonzalez-Hernandez; Michael D Swanson; Rafael Contreras-Galindo; Sarah Cookinham; Steven R King; Richard J Noel; Mark H Kaplan; David M Markovitz
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

3.  Transcellular transactivation by the human immunodeficiency virus type 1 tat protein.

Authors:  D E Helland; J L Welles; A Caputo; W A Haseltine
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity.

Authors:  R Cantin; J F Fortin; G Lamontagne; M Tremblay
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells.

Authors:  Ann Apolloni; Min-Husan Lin; Haran Sivakumaran; Dongsheng Li; Michael H R Kershaw; David Harrich
Journal:  Hum Gene Ther       Date:  2013-03-01       Impact factor: 5.695

6.  Repression of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by binding of the virus to its primary cellular receptor, the CD4 molecule.

Authors:  P Bérubé; B Barbeau; R Cantin; R P Sékaly; M Tremblay
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

7.  Interference to human immunodeficiency virus type 1 infection in the absence of downmodulation of the principal virus receptor, CD4.

Authors:  D J Volsky; M Simm; M Shahabuddin; G Li; W Chao; M J Potash
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Differential growth kinetics are exhibited by human immunodeficiency virus type 1 TAR mutants.

Authors:  D Harrich; C Hsu; E Race; R B Gaynor
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Modulation of human immunodeficiency virus type 1-induced syncytium formation by the conformational state of LFA-1 determined by a new luciferase-based syncytium quantitative assay.

Authors:  B Barbeau; J F Fortin; N Genois; M J Tremblay
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

10.  Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1.

Authors:  Anna L Remoli; Giulia Marsili; Edvige Perrotti; Eleonora Gallerani; Ramona Ilari; Filomena Nappi; Aurelio Cafaro; Barbara Ensoli; Riccardo Gavioli; Angela Battistini
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.